{"prompt": "['Alliance A221701', 'study will mirror that of the main study. For the purpose of the correlative, we will compare', 'the difference in average PRO pain score within each arm separately and use each candidate', 'SNP that meets the threshold of the cutoff (as defined in section 14.1.3) as the primary', 'covariate of interest. The Bonferroni method will be applied to control the Type I error', 'rate at 5% for each of the different models. Markers that do not meet the threshold of the', 'cutoff will be summarized descriptively.', '54', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', '14.2 Population Pharmacokinetics (PK) of Everolimus A221701-PP1', '14.2.1 Background', 'In transplantation settings, where therapeutic drug monitoring (TDM) aided dose-', 'adjustment is common, everolimus should be generally targeted to a trough concentration', '(Co) of 3-8 ng/mL when used in combination with other immunosuppressive drugs', '(calcineurin inhibitors and glucocorticoids); in calcineurin inhibitor-free regimens, the', 'everolimus target C0 range should be 6-10ng/mL. Further studies are required to determine', 'the clinical utility of TDM in nontransplantation settings59. In oncology settings, 10 mg/day', 'seems to be the maximum tolerated dose. At this dose, everolimus C0 of up to 17.0 ng/mL', 'have been observed, with large interindividual differences. In patients with metastatic renal', 'cell carcinoma (n = 42), the median everolimus C0 was 14.1 ng/mL (range, 2.6-91.5', 'ng/mL). Fourteen (67%) versus 8 (38%) patients with median everolimus C0 above or', 'below 14.1 ng/ mL, respectively, were progression-free at 6 months (P =0.06); median', 'progression-free survival was 13.3 versus 3.9 months, respectively [hazard ratio (HR),', '0.66; 95% CI, 0.33-1.31; P = 0.23], and median overall survival was 26.2 versus 9.9', 'months, respectively (HR, 0.62; 95% CI, 0.28-1.37; =0.24).59', 'Everolimus is orally active, with linear (dose-proportional) PK. Absorption is rapid, with', 'peak concentration reached within 1.5-2 hours. The free fraction of everolimus (EVR) in', 'plasma is approximately 0.26. There is a good correlation between predose or C0 and area', 'under the concentration-time curve (AUC) at steady state. In blood, everolimus is highly', 'incorporated into erythrocytes, and there is evidence that this binding is concentration', 'dependent, justifying the use of whole blood rather than plasma for EVR quantification.', 'Everolimus has a long half-life of approximately 30 hours. Steady-state concentrations are,', 'therefore, generally achieved within 4-7 days.', 'Everolimus is a substrate of both the efflux pump known as the ATP-binding cassette', 'subfamily B member 1 (ABCB1; P-glycoprotein) and the CYP metabolic enzyme', '(particularly CYP3A4, with CYP3A5 and CYP2C8 playing minor roles). Everolimus is', 'prone to substantial PK variability and numerous drug-drug interactions because of the', 'involvement of ABCB1 and CYP3A4 in its PKs. Data regarding the effect of CYP3A4', 'genetic variations on EVR PK (or pharmacodynamics) are still scarce. The CYP3A4*IB', 'allele (rs2740574; c.-392G.A) showed no association with EVR dose-normalized', 'concentrations in lung transplant recipients. No significant influence on everolimus PK', 'was observed in relation to the CYP3A4*22 (rs35599367; c.522191C.T) variant, which was', 'found in 9 of 97 patients; 8 were heterozygous carriers and 1 was a homozygous carrier of', 'the CYP3A4*22 allele. Six studies have been reported to date, showing no association', 'between the common CYP3A5*3 allele (rs776746; c.219-237G.A) and everolimus blood', 'concentrations, dose requirement, or PK parameters estimated using population PK', 'approaches. No studies found a significant relationship between everolimus dosing or', 'blood concentrations and CYP2C8 genotype, which denotes 2 highly linked variants,', 'rs11572080 (c.416G.A; .R139K) and rs10509681 (c.1196A.G;p.K399R), occurring at', 'relatively high frequency in whites (11%-14%), but rarely in Asians and Africans. This is', 'consistent with its minor role in everolimus metabolism. A study in lung transplant', 'recipients failed to demonstrate any association with CYP2C8*2 (rs11572103: c.805A.T;', 'p.Ile199Phe) and CYP2C8*4 alleles (rs1058930: c. .792C.G; p.Ile264Met), and a study in', 'heart transplant recipients found no association between CYP2C8*3 and everolimus', 'adverse effects. Three pharmacogenetic studies also investigated the effects of ABCBI', 'genetic polymorphisms on everolimus PK in solid organ transplantation and none reported', 'significant associations.', '55', 'NCI version date 8/14/2020', 'Update #03']['Alliance A221701', 'Population PK models of everolimus have been developed. A model in heart transplant', 'recipients reported an apparent clearance and distribution volume of 3.33 0.20 L/h and', '146 33 L, respectively, and a significant influence of bilirubin concentration on', 'clearance. In kidney transplant recipients, using a 2-compartment structural model with', 'first-order absorption with lag time, ideal body weight was found to be significantly related', 'to the volume of distribution.', 'The intrapatient PK variability of everolimus is reported to be high (45% for Co, 27% for', 'the AUC in de novo kidney transplant recipients administered CsA), as is interindividual', 'variability (55% for Co, 31% for the AUC).', 'In a multiple-dose study in kidney transplant recipients, a high-fat meal delayed tmax by a', 'median of 1.75 hours and reduced Cmax by 53% and AUC by 21%. Everolimus C0 showed', 'no food effect, suggesting that although overall exposure is prone to a food effect, this does', 'not translate into C0 variations.', 'We believe we will find in this study that the interpatient variability in everolimus exposure', '(Co) exceeds 50% and that there is a correlation between everolimus exposure (C0) and its', 'toxicity and the use of dexamethasone.', '14.2.2 Objectives', '1. To determine the intrapatient and interpatient variability of everolimus exposure', '(Co) in cancer patients being treated with everolimus.', '2. To explore the association of everolimus exposure (Co) with toxicity', '14.2.3 Methods', 'Venous blood samples for everolimus trough concentrations (Co) will be obtained at', 'baseline, and at the 8 weeks scheduled follow-up clinic visit (and optional at 4 weeks)', 'while still receiving study drug therapy. These samples will have the time of day they were', 'obtained documented. At these follow up visits a patient questionnaire will be filled in', 'which will request information about the timing of prior dosing of everolimus (See', 'Appendix VIII). This will detail the time of day the last dose of study drug was taken.', 'Drug concentrations will be measured in whole blood using an Liquid Chromatography', 'Tandem-Mass Spectrometry (LC-MS-MS) assay to be implemented in the Alliance', 'Pharmacology/Pharmacokinetic core lab at the University of Pittsburgh using a', 'modification of e.g. the assay published by Tszyrsznic, W et al.6', 'Frequentist approaches will be used for correlation, and if data permits, population', 'modeling approaches may also be employed.', '14.2.4 Analyses', 'Objective 1: We will calculate C0 variability at 8 weeks as a metric of interpatient', 'variability; while the inclusion of data from 4 week samples will allow calculation of', 'intrapatient variability. We will approach this using a frequentist approach.', 'Objective 2: We will explore relationships between C0 and mucosal toxicity, and', 'dexamethasone use.', '56', 'NCI version date 8/14/2020', 'Update #03']\n\n###\n\n", "completion": "END"}